Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 5.26% is 50% below its 5-year average of 10.61%, around the middle of its 5-year range (-65.64%–75.90%).
52.96% below its 12-month average of 11.18%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 20.54%.
OPERATING MARGIN
5.26%
OPERATING MARGIN AVG TTM
11.18%
OPERATING MARGIN AVG 3Y
14.07%
OPERATING MARGIN AVG 5Y
10.61%
OPERATING MARGIN AVG 10Y
21.48%
OPERATING MARGIN AVG 15Y
26.76%
OPERATING MARGIN AVG 20Y
24.45%
CURRENT VS TTM AVG
-52.96%
CURRENT VS 3Y AVG
-62.61%
CURRENT VS 5Y AVG
-50.45%
CURRENT VS 10Y AVG
-75.51%
CURRENT VS 15Y AVG
-80.34%
CURRENT VS 20Y AVG
-78.48%
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Jazz Pharmaceuticals plc
Market Cap
$14.54B
Operating Margin
5.26%
TTM Avg
11.18%
3Y Avg
14.07%
5Y Avg
10.61%
Market Cap
$14.63B
Operating Margin
23.38%
TTM Avg
22.93%
3Y Avg
18.97%
5Y Avg
16.75%
Market Cap
$14.66B
Operating Margin
39.88%
TTM Avg
32.73%
3Y Avg
24.94%
5Y Avg
21.46%
Market Cap
$14.69B
Operating Margin
12.35%
TTM Avg
9.13%
3Y Avg
12.39%
5Y Avg
13.51%
Market Cap
$14.04B
Operating Margin
-18.92%
TTM Avg
-47.79%
3Y Avg
-341.06%
5Y Avg
-1987.98%
Market Cap
$15.07B
Operating Margin
24.99%
TTM Avg
19.38%
3Y Avg
20.05%
5Y Avg
20.47%
Market Cap
$13.81B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2556.35%
5Y Avg
-4397.07%
Market Cap
$13.11B
Operating Margin
-113.35%
TTM Avg
-190.29%
3Y Avg
-1892.24%
5Y Avg
-2358.01%
Market Cap
$13.01B
Operating Margin
56.77%
TTM Avg
56.39%
3Y Avg
48.50%
5Y Avg
51.69%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | $14.54B | 5.26% | 11.18% | 14.07% | 10.61% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 23.38% | 22.93% | 18.97% | 16.75% |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 39.88% | 32.73% | 24.94% | 21.46% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | 12.35% | 9.13% | 12.39% | 13.51% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | -18.92% | -47.79% | -341.06% | -1987.98% |
| Solventum Corporation (SOLV)vs › | $15.07B | 24.99% | 19.38% | 20.05% | 20.47% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | 0.00% | 0.00% | -2556.35% | -4397.07% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -113.35% | -190.29% | -1892.24% | -2358.01% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 56.77% | 56.39% | 48.50% | 51.69% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 0.77% | 13.08% | 19.11% | 24.45% |
Gross Margin
84.7%
Operating Margin
5.3%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 20.54% |
| 2026-03-31 | 20.00% |
| 2025-12-31 | 75.90% |
| 2025-09-30 | 5.11% |
| 2025-06-30 | -65.64% |
| 2025-03-31 | -6.23% |
| 2024-12-31 | 17.53% |
| 2024-09-30 | 24.67% |
| 2024-06-30 | 19.48% |
| 2024-03-31 | 7.34% |
| 2023-12-31 | 12.11% |
| 2023-09-30 | 17.73% |
| 2023-06-30 | 16.47% |
| 2023-03-31 | 14.12% |
| 2022-12-31 | -27.09% |
| 2022-09-30 | 2.63% |
| 2022-06-30 | 9.17% |
| 2022-03-31 | 10.76% |
| 2021-12-31 | 5.51% |
| 2021-09-30 | 3.38% |
| 2021-06-30 | -9.26% |
| 2021-03-31 | 26.68% |
| 2020-12-31 | 26.06% |
| 2020-09-30 | 32.65% |
| 2020-06-30 | 35.23% |
| 2020-03-31 | -35.47% |
| 2019-12-31 | 10.53% |
| 2019-09-30 | 24.75% |
| 2019-06-30 | 38.25% |
| 2019-03-31 | 26.32% |
| 2018-12-31 | 38.84% |
| 2018-09-30 | 40.22% |
| 2018-06-30 | 30.61% |
| 2018-03-31 | 19.75% |
| 2017-12-31 | 32.36% |
| 2017-09-30 | 20.99% |
| 2017-06-30 | 41.85% |
| 2017-03-31 | 36.20% |
| 2016-12-31 | 41.73% |
| 2016-09-30 | 36.41% |
| 2016-06-30 | 44.27% |
| 2016-03-31 | 36.06% |
| 2015-12-31 | 31.28% |
| 2015-09-30 | 38.59% |
| 2015-06-30 | 45.93% |
| 2015-03-31 | 37.75% |
| 2014-12-31 | 39.59% |
| 2014-09-30 | 18.93% |
| 2014-06-30 | 25.51% |
| 2014-03-31 | -27.00% |
| 2013-12-31 | 40.08% |
| 2013-09-30 | 43.31% |
| 2013-06-30 | 37.01% |
| 2013-03-31 | 34.75% |
| 2012-12-31 | 36.68% |
| 2012-09-30 | 31.51% |
| 2012-06-30 | 30.44% |
| 2012-03-31 | 32.97% |
| 2011-12-31 | 45.09% |
| 2011-09-30 | 45.99% |
| 2011-06-30 | 52.44% |
| 2011-03-31 | 44.43% |
| 2010-12-31 | 47.85% |
| 2010-09-30 | 32.27% |
| 2010-06-30 | 26.14% |
| 2010-03-31 | 20.55% |
| 2009-12-31 | 29.80% |
| 2009-09-30 | 12.04% |
| 2009-06-30 | 21.55% |
| 2009-03-31 | -32.72% |
| 2008-12-31 | -263.94% |
| 2008-09-30 | -156.34% |
| 2008-06-30 | -303.07% |
| 2008-03-31 | -299.36% |
| 2007-12-31 | -379.56% |
| 2007-09-30 | -82.88% |
| 2007-06-30 | -299.73% |
| 2007-03-31 | -138.30% |
| 2006-12-31 | -952.93% |
| 2006-09-30 | 100.00% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 100.00% |
| 2005-12-31 | -1366.16% |
| 2005-09-30 | 100.00% |
| 2005-06-30 | 100.00% |
| 2005-03-31 | 100.00% |
